Business Wire | Aug 4, 2020 04:45PM EDT

Geron to Present at the BTIG Virtual Biotechnology Conference

Aug. 04, 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 04, 2020--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 12:30 p.m. ET.

A live audio webcast of the presentation will be available on Geron's website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company's website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005949/en/

CONTACT: Suzanne Messere Investor and Media Relations investor@geron.com media@geron.com